

JC20 Rec'd PCT/PTO 07 OCT 2005

Attorney Docket # 33900-184PUS

Express Mail #EV129275698US

Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re National Phase PCT Application of
Pierre LEBRETON

Int'l PCT Serial No.: PCT/FR2004/000870

Int'l Filing Date:: 8 April 2004

For: Crosslinking of Low-Molecular Weight
and High-Molecular Weight
Polysaccharides; Preparation of Injectable
Monophase Hydrogels; Polysaccharides
and Hydrogels Obtained

INFORMATION DISCLOSURE STATEMENT

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

S I R:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56 and in accordance with the practice under 37 C.F.R. §§ 1.97 and 1.98, the Examiner's attention is directed to the documents listed on the enclosed Form PTO/SB/08a. Copies of the listed documents are also enclosed.

In accordance with 37 CFR § 1.99, a concise explanation of each foreign language reference may be found in the specification in the application as filed. In particular, an explanation of reference EP A-0 466 300 may be found on page 2 of the specification, and we have also included its U.S. equivalent, U.S. Patent No. 5,246,698; an explanation of reference WO-A-96 337 51 may be found on page 2 of the specification; an explanation of reference WO-A-00 014 28 may be found on page 2 of the specification, and we have also included its U.S. equivalent, U.S. Patent No. 6,685,963; an explanation of reference WO-A-98 356 39 may be

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.B./

found on page 2 of the specification, and we have also included its U.S. equivalent, U.S. patent No. 6,383,219; an explanation of reference WO-A-98 356 40 may be found on page 2 of the specification, and we have also included its U.S. equivalent, U.S. Patent No. 6,383,218; an explanation of reference US-A-4 716 154 may be found on page 2 of the specification; an explanation of reference WO 02/05753 may be found on page 3 of the specification; an explanation of reference no. WO-A-02 063 50 may be found on page 3 of the specification, and we have also included its U.S. equivalent, U.S. patent No. 6,921,819.

Some of the references submitted herewith have also been reported in the International Search Report on October 18, 2004 by the European Patent Office. However, reference LAMAR, P.D. ET AL.: "Antifibrosis Effect of Novel Gels in Anterior Ciliary Sclerotomy (ACS)" is cited as an "A" reference in the International Search Report. It is believed that this constitutes a concise explanation of the relevance of this reference in accordance with 37 C.F.R. § 1.98(a)(3). However, if to consider this reference the Examiner requires additional information, a further concise explanation will be provided upon the Examiner's request.

The enclosed copy of Canadian Patent No. 949 965 is a copy of the document as provided with the International Search Report.

In accordance with 37 C.F.R §§1.97(g) and (h), the filing of this Information Disclosure Statement should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56(b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant(s) reserve(s) the right to prove that the date of publication is in fact different.


ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.B./

JC20 Rec'd PCT/PTO 07 OCT 2005

It is respectfully requested that the above information be considered by the
Examiner and that the copy of the enclosed Form PTO/SB/08a be returned indicating that such
information has been considered.

Respectfully submitted,
COHEN, PONTANI, LIEBERMAN & PAVANE

By


Edward M. Weisz
Reg. No. 37,257
551 Fifth Avenue, Suite 1210
New York, New York 10176
(212) 687-2770

Dated: October 7, 2005

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/552309
		Filing Date	
		First Named Inventor	Pierre LEBRETON
		Art Unit	
Sheet 1 of 2		Examiner Name	
		Attorney Docket Number	33900-184PUS

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. 1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind-Code ² (if known)			
		US-4,582,865	04-15-1986	Balazs et al.	
		US-5,531,716	07-02-1996	Luzio et al.	
		US-4,996,787	12-12-1989	de Belder et al.	
		US-5,246,698	09-21-1993	Leshchiner et al.	
		US-6,685,963	02-03-2004	Taupin et al.	
		US-6,383,219	05-07-2002	Telandro et al.	
		US-6,383,218	05-07-2002	Sourdille et al.	
		US-4,716,154	12-29-1987	Mälson et al.	
		US-6,921,819	07-26-2005	Piron et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. 1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind-Code ⁵ (if known)				
		CA 949 965	6-25-1974			✓
		WO 96/33751	10-31-1996			✓
		WO 02/05753	01-24-2002			English abstract only

Examiner Signature	/Layla Bland/	Date Considered	08/27/2008
--------------------	---------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.B./

5010-104/2003. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /L.B./